Tackling metabolic defects in HFpEF

Key Points

• This research aims to address metabolic defects associated with heart failure with preserved ejection fraction (HFpEF).
• Conducted a randomized trial with interventions aimed at metabolic pathways related to HFpEF.
• Engaged a population diagnosed with HFpEF and assessed their clinical outcomes.
• Utilized biomarkers to track changes before and after the intervention.
• Significant reduction in metabolic defects observed post-intervention, with an effect size (RR) of 0.75, 95% CI [0.60-0.90], P=0.02.
• Improved clinical outcomes, including enhanced exercise capacity and quality of life indicators, were noted post-treatment.